Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935663 | 0.94 | HPGD (0.56) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL56416 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1335071 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL57238 | 0.90 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL13391819 | 0.85 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL3088856 | 0.85 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL18340953 | 0.84 | HPGD (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31095755 | 0.82 | KDM4E (0.42) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1333807 | 0.82 | NR1H2 (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL191075 | 0.82 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630524-B2 | Pleuromutilin in derivatives for treating viral infections | ARIVA MED GMBH (AT) | 2026-05-19 | — | — | US | disclosed |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2026-05-07 | — | — | US | disclosed |
| US-12522597-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4135683-B9 | ANTIVIRAL USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2025-12-10 | — | — | EP | disclosed |
| EP-4135683-B1 | ANTIVIRAL USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2025-09-17 | — | — | EP | disclosed |
| EP-4562007-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-111699176-B | Quinazolinones as PARP14 inhibitors | 里邦医疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| US-20010031778-A1 | Triazole antifungal agent | SANKYO COMPANY LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
| US-6300357-B1 | FOR THERAPY OF MYCOTIC DISEASE OF A HUMAN BEING AND AN ANIMAL | SANKYO COMPANY, LIMITED (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-0841327-B1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| US-5977152-A | Triazole antifungal agent | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| CN-1227540-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY CO LTD (GB) | 1999-09-01 | — | — | CN | disclosed |
| EP-0841327-A1 | TRIAZOLE ANTIFUNGAL AGENT | SANKYO COMPANY LIMITED (JP) | 1998-05-13 | — | — | EP | disclosed |
| EP-0500835-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE. | DAE WOONG PHARMA (KR) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004342-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | HPGD 658/4885RECQL 538/4885EPHX1 4018/4885 |
| US-12630524-B2 | Pleuromutilin in derivatives for treating viral infections | MLN, PLEC, PELP1 | HPGD 4332/4885RECQL 3352/4885EPHX1 1502/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | HPGD 1541/4885RECQL 850/4885EPHX1 4055/4885 |
| US-20260125362-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP16, PARP11 | HPGD 3564/4885RECQL 387/4885EPHX1 4222/4885 |
| US-20010031778-A1 | Triazole antifungal agent | ERG28, NAT1, RIF1 | HPGD 4407/4885RECQL 2070/4885EPHX1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.